First Trust Nasdaq Semiconductor ETF (NASDAQ: FTXL)

Últimas noticias sobre First Trust Nasdaq Semiconductor ETF (NASDAQ:FTXL)

First Trust Nasdaq Semiconductor ETF

Technology

The fund invests at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the semiconductor sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.

Nvidia Corp

Broadcom Inc

Qualcomm Inc.

Applied Materials, Inc.

Texas Instruments Inc

Analog Devices, Inc.

Kla Corp.

Skyworks Solutions Inc.

Nxp Semiconductors N V

Intel Corp.

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 19.07% at $2.49</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 12.24% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 10.75% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 5.70% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 4.58% at $20.11</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 4.53% at $0.29</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 3.11% at $2.83</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 36.87% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 17.24% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 16.13% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 6.53% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 4.89% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 4.68% at $0.06</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

CARA

CBDY

CNBX

CRBP

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

ELLXF

FUAPF

KAYS

LMLLF

OILFF

TGIFF

XXII

Cannabis Stock Movers For October 2, 2024

News

Asset Sales

Trading Ideas

LEVI

Levi Strauss Begins Strategic Review For Dockers Brand, Exploring Potential Sale Or Other Strategic Transactions; Bank Of America Retained As Financial Advisor; No Set Deadline Or Guarantee Of Any Outcome

Momentum and value investing are two distinct investment approaches with their own strengths and risks. While momentum investing relies on following existing price trends, value investing focuses on identifying undervalued shares before a market correction. Read on to learn more about the differences between these two strategies &mdash; and which might be best for you.&nbsp;
<h2>What Is Momentum Investing?</h2>
Momentum investing is a strategy where investors buy stocks or other assets that have shown an upward price trend and sell those that are falling. The idea is that assets that have performed well in the recent past will continue to perform well in the near future, while underperforming assets will continue to decline. This strategy is based on the belief that trends in asset prices tend to persist over time due to investor behavior, market psychology, and sometimes economic factors. Investors typically cut losses quickly and secure profits early to avoid sharp market reversals.
<h3>Key Traits of Momentum Investing</h3>
&nbsp;To identify and capitalize on price trends, momentum investors will typically:
<ul>
<li>
Focus on Price Trends
</li>
<li>
Have Short- to Medium-Term Holding Periods
</li>
<li>
Emphasize Relative Strength
</li>
<li>
Use Technical Analysis
</li>
<li>
Monitor Trading Volume
</li>
<li>
Employ Strong Risk Management
</li>
<li>
High Portfolio Turnover
</li>
</ul>
<h2>What is Value Investing?</h2>
Value investing is a more conservative strategy that involves evaluating a company&#39;s financial and long-term health. Value investors identify undervalued companies and buy shares at a reduced price, hoping the market will eventually correct the mispricing and recognize the asset&#39;s true worth.
<h3>Key Traits of Value Investing</h3>
Instead of following trends like momentum investors, value investors will typically:
<ul>
<li>
Seek Undervalued Assets
</li>
<li>
Maintain a Long-Term Investment Horizon
</li>
<li>
Rely on Fundamental Analysis
</li>
<li>
Prioritize a Margin of Safety
</li>
<li>
Exercise Patience and Discipline
</li>
<li>
Favor Stable, Established Companies
</li>
<li>
Adopt a Risk-Averse Approach
</li>
</ul>
<h2>Differences Between Momentum and Value Investing</h2>
Momentum and value investing offer contrasting approaches to the stock market, each with unique characteristics suited to different investors and market conditions.
<h3>Investment Philosophy</h3>
The core difference between momentum and value investing lies in their investment philosophy.
Momentum investing is based on the belief that trends will continue. Investors buy assets that are rising in price and sell those that are falling, aiming to profit from the continuation of these trends. It is driven by market psychology and the assumption that upward or downward momentum will continue due to investor behavior and herd mentality.
Value investing, by contrast, is built on the principle that the market sometimes misprices stocks. Value investors believe that over time, the market will correct these mispricings, and the stock&#39;s price will rise to reflect its true intrinsic value. This approach is rooted in patience and the idea that sound fundamentals will eventually prevail over market noise.
<h3>Time Horizon</h3>
Momentum investors will typically hold stocks for weeks or months, looking to capitalize on quick price movements before the trend reverses. They focus on taking advantage of short-term market conditions and frequently adjust their portfolios to respond to new trends.&nbsp;
Value investing, on the other hand, has a much longer time horizon. Value investors are willing to wait years for the market to recognize a company&#39;s true value. Their goal is not to chase quick gains but to hold quality stocks that will appreciate slowly and steadily over time, benefiting from both price correction and long-term growth.
<h3>Analysis Type</h3>
Momentum investing relies heavily on technical analysis, which involves studying price charts, market trends, and trading volume. Momentum traders use indicators like moving averages, relative strength indexes (RSI), and other technical tools to identify entry and exit points. Their focus is more on price patterns and historical data than on the financial health of a company.
Value investing focuses on long-term potential rather than short-term price action. Value investors perform fundamental analysis on a company by examining its earnings, book value, cash flow, and debt. They compare the company&#39;s intrinsic value to its market price to identify if it is undervalued.
<h3>Risk Level</h3>
Due to its reliance on short-term price movements, momentum investing is generally considered a high-risk strategy.&nbsp;Since trends can reverse quickly, momentum traders face the risk of sharp downturns and rapid losses if they fail to exit positions in time. Moreover, because momentum is largely influenced by market sentiment and investor behavior, it can be unpredictable and volatile.
Value investing tends to be lower risk because it focuses on finding discounted stocks that are fundamentally sound. By buying stocks at a discount to their intrinsic value, value investors create a &quot;margin of safety&quot; which can protect against downside risk. Although value stocks may take longer to appreciate, they are generally viewed as more stable and less susceptible to extreme volatility than momentum-driven stocks.
<h3>Market Behavior</h3>
Whether the market is bullish or bearish, as long as clear trends are established, momentum investors can profit. They rely on the assumption that prices will continue to move in their current direction, making this strategy particularly effective during periods of significant market momentum and sentiment-driven trading.
Value investors, by contrast, often succeed in markets with mispricings, especially during downturns or corrections when stocks may be temporarily undervalued. In volatile or bear markets, value investors may find more opportunities as others sell stocks that are temporarily out of favor.
<h3>Source of Returns</h3>
Momentum investors seek to profit from market timing, buying stocks that are on the rise and selling them before the trend reverses. They rely on quick shifts in stock prices and can often experience rapid gains (or losses) over short periods.
By purchasing stocks at a discount to their intrinsic value, value investors profit when the stock price rises to reflect its true worth. In addition, value stocks often pay dividends, providing another steady source of income over the long term.
<h2>Momentum vs. Value Investing: Which Is Better?</h2>
Neither strategy is inherently better than the other; each has its advantages depending on market conditions and individual investor preferences. Value investing appeals to those with a long-term, conservative approach. It is also a more forgiving strategy for beginner or less active investors since the longer general time frame allows prices to rebound before major goals like retirement. Momentum investing is more suited to those comfortable with higher risk and short-term market movements. While this strategy is riskier compared to value investing, momentum investors may be able to take profits more quickly &mdash; ideal if you&#39;re investing for a shorter-term goal, like buying a new car.&nbsp;
As always, consider your risk tolerance, investment time frame, and goals when choosing the right strategy for you. Consulting a financial advisor may also help you determine which method aligns with your objectives.
The article &quot;<a href="https://www.marketbeat.com/learn/momentum-vs-value-investing/">Momentum vs. Value Investing: What&#39;s the Difference?</a>&quot; first appeared on MarketBeat.

Education

Personal Finance

General

Momentum vs. Value Investing: What's the Difference?

Earnings

SYNX

Silynxcom H1 2024 Revenue $5.35M

WIIM

PCSA

Processa Pharmaceuticals shares are trading higher after the company announced the dosing of its first patient for the Phase 2 trial of NGC-Cap.

Biotech

GMED

Globus Medical Launches New Orthopedic Trauma Solutions Including TENSOR Suture Button, ANTHEM II Distal Radius Volar Plates, And AUTOBAHN Trochanteric Nail PRO Instruments

Arcosa, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aca#NYSE">ACA</a>) recently acquired the construction materials business of Stavola Holding Corporation and its affiliated entities (Stavola) for $1.2 billion.
This apart, ACA completed the previously announced sale of its steel components business on Aug. 16, 2024.
<h2>Buyout Synergies</h2>
The acquisition was funded with a $600 million 6.875% Senior Note issuance (due 2032), which closed on Aug. 26, 2024, and a pre-payable $700 million variable-rate senior secured Term Loan B Facility (due 2031), which was funded concurrently with the closing of the transaction. Excess cash proceeds will be used to pay down borrowings on the company&#39;s revolving credit facility.
For third-quarter 2024, the company expects adjusted EBITDA to be within $1-$1.5 million loss, reflecting a partial period of ownership that was impacted by the deferral of certain product shipments and business interruption from actions necessary to complete the divestiture process. Moreover, Arcosa plans to update its 2024 revenue and adjusted EBITDA guidance for the completion of these transactions at third-quarter earnings release.
The company anticipates deploying strong free cash flow to return to its net leverage target of 2.0-2.5X within 18 months.
<h2>About Stavola</h2>
Founded in 1948, Stavola is an aggregates-led and vertically integrated construction materials company. It primarily serves the New York-New Jersey Metropolitan Statistical Area&nbsp;through its network of five hard rock natural aggregates quarries, 12 asphalt plants and three recycled aggregates sites.
In the past 12 months (ended June 30, 2024), Stavola generated revenues of $283 million and adjusted EBITDA of $100 million, representing an adjusted EBITDA margin of 35%. Of the total adjusted EBITDA, 56% was contributed by the aggregates business. This is expected to create tax benefits attributable to Arcosa with a net present value of nearly $125 million.
Antonio Carrillo, president and chief executive officer of ACA, stated, &quot;These transactions significantly advance our strategy of growing in attractive markets while reducing the cyclicality and complexity of our overall portfolio. Stavola underscores our aggregates-led acquisition strategy, expanding our platform into the nation&#39;s largest MSA with industry-leading financial attributes.&quot;
<h2>ACA&#39;s Stock Performance</h2>
Shares of this Zacks Rank #3 (Hold) company have soared 11.6% in the past six months compared with the Zacks Building Products - Miscellaneous industry&#39;s 6.6% growth. Solid contributions from its Construction Products and Engineered Structures segments boosted growth. A boost in infrastructural and public construction spending, along with a renewable energy drive, should improve Arcosa&#39;s growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/17/80058.jpg?v=925353102" />
Image Source: Zacks Investment Research
Arcosa strategically pursued two acquisitions in the first half of 2024, significantly bolstering its performance. In August, the company entered into a deal with an affiliate of Stellex Capital Management, a middle-market private equity firm, to sell its McConway &amp; Torley and Standard Forged Products businesses.
These inorganic moves align with Arcosa&#39;s long-term growth strategy, aiming to capitalize on opportunities in key markets and sectors. As the company continues to integrate these acquisitions, it anticipates further synergies and operational efficiencies, thus driving value for shareholders.
In a nutshell, Arcosa&#39;s strategic acquisitions have positioned it for sustained growth and market leadership in the construction products sector, underscoring its commitment to delivering innovative solutions and creating value for stakeholders.
<h2>Key Picks</h2>
Latham Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swim#NASDAQ">SWIM</a>): Based in Latham, NY, the company stands as the leading designer, manufacturer and marketer of in-ground residential swimming pools and pool accessories. It presently sports a Zacks Rank #1 (Strong Buy).
SWIM has seen an upward estimate revision for 2024 earnings per share to 13 cents from break-even over the past 60 days. The estimated figure indicates 750% year-over-year growth.
Armstrong World Industries, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/awi#NYSE">AWI</a>): Based in Lancaster, PA, Armstrong World is a leading global manufacturer of ceiling systems primarily for commercial, institutional and residential building construction and renovation. It presently carries a Zacks Rank #2 (Buy).
AWI has seen an upward estimate revision for 2024 EPS to $6.07 from $6.02 over the past 60 days. The estimated figure indicates 14.1% year-over-year growth.
Frontdoor, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ftdr#NASDAQ">FTDR</a>): Based in Memphis, TN, this company provides home warranties in the United States. It presently carries a Zacks Rank of 2.
FTDR has seen an upward estimate revision for 2024 EPS to $2.79 from $2.64 over the past 60 days. The estimated figure indicates 21.3% year-over-year growth.
<a href="https://www.zacks.com/stock/news/2344956/arcosa-acquires-stavola-for-1-2b-divests-steel-components-business?cid=CS-BENZ-FT-analyst_blog|company_news_corporate_actions-2344956">To read this article on Zacks.com click here.</a>

Mid Cap

Guidance

Small Cap

Analyst Ratings

FTDR

SWIM

Arcosa Acquires Stavola for $1.2B, Divests Steel Components Business

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">and individual tickers.</a>
Here is a look at the most-searched stocks on Benzinga Pro for September 2024. Current prices and year-to-date performance are based on Sept. 30 and do not include dividends.
1. NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ol></ol>
<ol></ol>
<ol></ol>
<ol></ol>
<ul>
<li>Current Price: $121.44</li>
<li>52-Week Range: $39.23 to $140.76</li>
<li>Year-to-Date Return: +152.1%</li>
<li><a href="https://www.benzinga.com/top-stories/24/07/39579249/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-june-where-do-nvidia-gamestop-tesla-apple">June</a>/<a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow">July</a>/<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n">August </a>Ranking: 1st/2nd/1st</li>
</ul>
2. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>Current Price: $573.76</li>
<li>52-Week Range: $409.22 to $574.71</li>
<li>Year-to-Date Return: +21.4%</li>
<li>June/July/August Ranking: 3rd/3rd/2nd</li>
</ul>
3. Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>Current Price: $261.63</li>
<li>52-Week Range: $138.80 to $271.00</li>
<li>Year-to-Date Return: +5.3%</li>
<li>June/July/August Ranking: 4th/1st/3rd</li>
</ul>
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100224">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
4. Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
<ul>
<li>Current Price: $233.00</li>
<li>52-Week Range: $164.08 to $237.23</li>
<li>Year-to-Date Return: +25.5%</li>
<li>June/July/August Ranking: 5th/7th/6th</li>
</ul>
5. Wheeler Real Estate Investment Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)
<ul>
<li>Current Price: $8.09</li>
<li>52-Week Range: $2.90 to $1,126.80</li>
<li>Year-to-Date Return: -92.8%</li>
<li>June/July/August Ranking: Not in Top 20 in any</li>
</ul>
6. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
<ul>
<li>Current Price: $488.07</li>
<li>52-Week Range: $342.35 to $503.52</li>
<li>Year-to-Date Return: +21.2%</li>
<li>June/July/August Ranking: 11th/11th/9th</li>
</ul>
7. Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul>
<li>Current Price: $416.40</li>
<li>52-Week Range: $226.59 to $1,229.00</li>
<li>Year-to-Date Return: +45.9%</li>
<li>June/July/August Ranking: 10th/19th/4th</li>
</ul>
8. Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>)
<ul>
<li>Current Price: $6.86</li>
<li>52-Week Range: $2.73 to $23.80</li>
<li>Year-to-Date Return: +29.9%</li>
<li>June/July/August Ranking: Not in Top 20 in any</li>
</ul>
9. Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)
<ul>
<li>Current Price: $23.46</li>
<li>52-Week Range: $18.51 to $51.28</li>
<li>Year-to-Date Return: -50.9%</li>
<li>June/July/August Ranking: Not in Top 20 in any</li>
</ul>
10. Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>)
<ul>
<li>Current Price: $8.05</li>
<li>52-Week Range: $2.09 to $13.25</li>
<li>Year-to-Date Return: +241.1%</li>
<li>June/July/August Ranking: Not in Top 20/Not in Top 20/20th</li>
</ul>
Honorable Mentions:&nbsp;The following stocks were the 11th&nbsp;to 20th&nbsp;most-searched tickers on&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;in September 2024.
11. Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)
12. Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
13. Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)
14. Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>)
15. CN Energy Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>)
16. Quhuo Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QH#NASDAQ">QH</a>)
17. ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>):
18. Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>)
19. Immuneering Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>)
20. Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)
Why It&#8217;s Important:&nbsp;Nvidia was the top searched stock on Benzinga Pro for the month of September once again. The stock has ranked first or second for every month tracked since February, sometimes alternating with SPY or Tesla.
The SPDR S&amp;P 500 ETF Trust ranked second for a second straight month, which comes as the S&amp;P 500 tracking index hit new all-time highs in the month of September.
Tesla, which topped the month of July, has ranked third for two straight weeks. The stock has ranked among the top four stocks searched in each month tracked in 2024.
The bigger story in September were the newcomers and the stocks that dropped off.
Newcomers to the top 10 included Wheeler Real Estate, Galmed, Intel and Intuitive. Of the four stocks, only Intuitive had ranked in the top 20 over the last three months. The newcomers all had catalysts in the last month that made their stocks highly volatile.
On the 11th through 20th portion of the list, the stocks were all different from the previous month with Intuitive moving to the top 10 and Palantir going from 7th to 12th and the other stocks all new to the top 20.
Several of the companies ranked in the bottom part of the top 20 are penny stocks trading at less than $5 per share that saw wide moves that saw increased interest from Benzinga traders.
One of the bigger names to make the top 20, by name recognition, is Trump Media &amp; Technology Group, the company that counts former President Donald Trump as a co-founder. The stock has been highly volatile during the 2024 election cycle.
Dropping out of the top 10 were Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>), Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) and the aforementioned Palantir.
Other big names that exited the top 20 include Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) that was 13th in August and fell to 24th to narrowly miss the list.
Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), which has frequently appeared in the top 20 and was ranked 15th in August dropped out of the top 20.
Overall the month of September saw six of the same top 10 tickers from August and eight of the top 20 tickers from August.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/07/39603613/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-first-half-2024-where-do-nvidia-tesla-pala">EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In First Half 2024 – Where Do Nvidia, Tesla, Palantir, GameStop Rank?</a></li>
</ul>
Image: Shutterstock

Exclusives

AAPL

AMZN

APLD

CNEY

GLMD

GOVX

IMRX

INTC

LUMN

LUNR

NDRA

NVDA

PLTR

SMCI

SMMT

TNON

TSLA

WHLR

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

Enhanced Community Development Awarded $65M In New Markets Tax Credits Program

Management

BIGC

BigCommerce Appoints Travis Hess As CEO, Replacing Brent Bellm; Ellen Siminoff Named Executive Chair Of The Board; Reaffirms Q3 2024 Financial Guidance

Texas Pacific Land Closes Acquisition Of Permian Oil And Gas Mineral And Royalty Interests For $286M Cash

ICUI

ICU Medical Appointed Daniel Woolson As President

The acquisition of this significant&nbsp;New York City&nbsp;based team continues FNF&#39;s strategy of acquiring the best companies and talent in the industry and bringing them into its portfolio to better service commercial real estate clients. &nbsp;
As part of the acquisition, FNTA&#39;s key commercial leadership team will join FNF, including&nbsp;Steven Napolitano,&nbsp;Devin Dregne, Esq.,&nbsp;Michael Ehrhardt,&nbsp;Michael Elkins, Esq.,&nbsp;Jesse Iadanza, Esq.,&nbsp;Michael Lebovitz,&nbsp;Michael Scott, Esq.,&nbsp;Matthew Emanuelo, and&nbsp;Chris Suozzi. Napolitano, who serves as FNTA&#39;s President and CEO, has over 35 years of industry experience and will continue to lead the company&#39;s day-to-day operations under FNF&#39;s ownership. This continuity will ensure a seamless transition for clients while maintaining FNTA&#39;s signature level of service.&nbsp;

Fidelity National Financial Reports Acquisition Of Commercial Operations Of First Nationwide Title Agency; No Terms Disclosed

Levi Strauss Sees FY24 Adj. EPS At Mid-Point Of $1.17-$1.27 Vs $1.25 Est.

Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.31 by 6.45 percent. The company reported quarterly sales of $1.516 billion which missed the analyst consensus estimate of $1.550 billion by 2.21 percent. This is a 0.33 percent increase over sales of $1.511 billion the same period last year.

Earnings Beats

Earnings Misses

Levi Strauss Q3 2024 Adj. EPS $0.33 Beats $0.31 Estimate, Sales $1.516B Miss $1.550B Estimate

Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares are trading higher Wednesday amid increased trading volume and gaining traction across social media platforms. 
Here&#8217;s <a href="https://www.benzinga.com/news/24/10/41144935/rpm-international-posts-upbeat-earnings-joins-joby-aviation-ciena-and-other-big-stocks-moving-higher">what you need to know.</a>
Counterpart Health Agreement with The Iowa Clinic: Last month, Clover Health&#8217;s subsidiary, Counterpart Health, announced a multi-year agreement with The Iowa Clinic. Clinicians serving The Iowa Clinic's Medicare Advantage and Medicare Shared Savings Program patients will utilize Counterpart Assistant, an AI-driven solution designed to integrate into physicians' workflows and facilitate the early diagnosis and management of chronic diseases.
The technology will also be available to The Iowa Clinic's clinically integrated network partners throughout the Midwest. Counterpart Health will receive a per-member, per-month fee and possible incentive payments tied to meeting specific care management objectives. 
Ben Vallier, CEO of The Iowa Clinic, praised Counterpart's ability to harness clinical data for improved outcomes and its intuitive design tailored to clinicians&#8217; needs.
Appointment of New COO: Clover Health also announced Joseph Brand as the new chief operating officer for its Medicare Advantage operations. Brand brings nearly 20 years of healthcare leadership experience, most recently serving as COO at Jefferson Health Plans. His focus will be on improving health care delivery in New Jersey through operational efficiencies and technological innovation.
<ol>
<li></li>
</ol>
What Else: Clover Health&#8217;s short interest has decreased by 9.75% since the last report, with 29.36 million shares shorted, representing 7.31% of the float. Traders on social media platforms, particularly Reddit's r/WallStreetBets, have been actively discussing Clover Health.
CLOV Price Action: Clover Health shares were up by 29.14% at $3.59 at publication Wednesday, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="538" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02155228/CLOV-1024x538.png" alt="" class="wp-image-577343" style="width:548px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02155228/CLOV-1024x538.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02155228/CLOV-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02155228/CLOV-768x403.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02155228/CLOV.png 1087w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<a href="https://www.benzinga.com/personal-finance/24/10/41149888/are-you-richer-than-your-friends-heres-how-to-tell-without-asking">Are You Richer Than Your Friends? Here&#8217;s How To Tell Without Asking</a>
Photo By CloverHealth Inc.

Health Care

CLOV

Clover Health Stock Surges Over 29% On High Volume: Recap

These funds are in addition to the&nbsp;$73.2 million&nbsp;in cash, cash equivalents and investments on hand as of June 30, 2024.&nbsp;In addition to the financing, the Company strengthened its management team through the appointments of Alison Moore&nbsp;to the newly created role of Chief Technology Officer and Georgia Erbez as Chief Financial Officer.

CDXS

Codexis Reports Increase In Its Cash Reserves Through Capital Raises Totaling $31M Via Existing ATM Facility, Bringing Cash Runway Into 2027; Georgia Erbez Named As CFO

Levi Strauss & Co shares are trading lower. The company reported Q3 financial results.

RCUS

Arcus Biosciences Announces Clinical Trial Collaboration Agreement With AstraZeneca To Evaluate Casdatifan In Combination With Volrustomig In Renal Cell Carcinoma

Processa Pharmaceuticals Doses First Patient In Phase 2 Trial Of NGC-Cap For Metastatic Breast Cancer To Compare Safety-Efficacy Against Capecitabine And Determine Optimal Dosage Regimen

Tech And AI Investing Trends: A Stock Picker's Take

How To Invest In AI Vs. Tech In A Portfolio

U.S. Equity Market Betas - Why They Matter And How They Are Changing

Chip stocks are in focus ahead of MU earnings and the Meta Connect 2024 conference

After a brief dip this summer, semiconductor stocks are heating up again, as mainstays in the space like Micron ($MU) post blowout earnings due to ...

SMH vs. FTXL: Which Semiconductor ETF Is Better?

The Tailwinds Of September

First Trust Nasdaq Semiconductor ETF declares quarterly distribution of $0.1017

China Goes Big And Fuels More Stock Market Gains; The S&P 500 Has Only Done This 7 Times Before

Can Big Tech's AI Ambitions Continue To Drive Markets Higher?

Biden-Harris administration to award up to $100M to boost AI use for semiconductor materials

Comments

First Trust Nasdaq Semiconductor ETF

Noticias

Últimas noticias sobre First Trust Nasdaq Semiconductor ETF (NASDAQ:FTXL)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL